The global Sickle Cell Disease (SCD) Treatment Market, valued at US$ 2.7 billion in 2023, is projected to grow at a compound annual growth rate (CAGR) of 18.5% from 2024 to 2034, surpassing US$ 17.7 billion by 2034. SCD, a hereditary blood disorder caused by a hemoglobin gene mutation, leads to sickle-shaped red blood cells, causing anemia, pain crises, and organ damage. The market is driven by...